|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Urick ME and Bell DW: Clinical
actionability of molecular targets in endometrial cancer. Nat Rev
Cancer. 19:510–521. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brooks RA, Fleming GF, Lastra RR, Lee NK,
Moroney JW, Son CH, Tatebe K and Veneris JL: Current
recommendations and recent progress in endometrial cancer. CA
Cancer J Clin. 69:258–279. 2019.PubMed/NCBI
|
|
4
|
Shahid RK, Ahmed S, Le D and Yadav S:
Diabetes and cancer: Risk, challenges, management and outcomes.
Cancers (Basel). 13:57352021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lam C, Low JY, Tran PT and Wang H: The
hexosamine biosynthetic pathway and cancer: Current knowledge and
future therapeutic strategies. Cancer Lett. 503:11–18. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ma J, Wu C and Hart GW: Analytical and
biochemical perspectives of protein O-GlcNAcylation. Chem Rev.
121:1513–1581. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang X and Qian K: Protein
O-GlcNAcylation: Emerging mechanisms and functions. Nat Rev Mol
Cell Biol. 18:452–465. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang YH, Weng CL and Lin KI:
O-GlcNAcylation and its role in the immune system. J Biomed Sci.
27:572020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akimoto Y, Yan K, Miura Y, Tsumoto H, Toda
T, Fukutomi T, Sugahara D, Kudo A, Arai T, Chiba Y, et al:
O-GlcNAcylation and phosphorylation of β-actin Ser199 in
diabetic nephropathy. Am J Physiol Renal Physiol. 317:F1359–F1374.
2019. View Article : Google Scholar
|
|
10
|
Nie H and Yi W: O-GlcNAcylation, a sweet
link to the pathology of diseases. J Zhejiang Univ Sci B.
20:437–448. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee BE, Suh PG and Kim JI: O-GlcNAcylation
in health and neurodegenerative diseases. Exp Mol Med.
53:1674–1682. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Quik M, Hokke CH and Everts B: The role of
O-GlcNAcylation in immunity against infections. Immunology.
161:175–185. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee JB, Pyo KH and Kim HR: Role and
function of O-GlcNAcylation in cancer. Cancers (Basel).
13:53652021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ferrer CM, Lynch TP, Sodi VL, Falcone JN,
Schwab LP, Peacock DL, Vocadlo DJ, Seagroves TN and Reginato MJ:
O-GlcNAcylation regulates cancer metabolism and survival stress
signaling via regulation of the HIF-1 pathway. Mol Cell.
54:820–831. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun L, Lv S and Song T: O-GlcNAcylation
links oncogenic signals and cancer epigenetics. Discov Oncol.
12:542021. View Article : Google Scholar
|
|
16
|
Jaskiewicz NM and Townson DH:
Hyper-O-GlcNAcylation promotes epithelial-mesenchymal transition in
endometrial cancer cells. Oncotarget. 10:2899–2910. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ciesielski P, Jóźwiak P, Forma E and
Krześlak A: TET3- and OGT-dependent expression of genes involved in
epithelial-mesenchymal transition in endometrial cancer. Int J Mol
Sci. 22:132392021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma S, Meng Z, Chen R and Guan KL: The
Hippo pathway: Biology and pathophysiology. Annu Rev Biochem.
88:577–604. 2019. View Article : Google Scholar
|
|
19
|
Wang S, Zhou L, Ling L, Meng X, Chu F,
Zhang S and Zhou F: The crosstalk between Hippo-YAP pathway and
innate immunity. Front Immunol. 11:3232020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ibar C and Irvine KD: Integration of
Hippo-YAP signaling with metabolism. Dev Cell. 54:256–267. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Piccolo S, Dupont S and Cordenonsi M: The
biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev.
94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Misra JR and Irvine KD: The Hippo
signaling network and its biological functions. Annu Rev Genet.
52:65–87. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dey A, Varelas X and Guan KL: Targeting
the Hippo pathway in cancer, fibrosis, wound healing and
regenerative medicine. Nat Rev Drug Discov. 19:480–494. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chao ML, Luo S, Zhang C, Zhou X, Zhou M,
Wang J, Kong C, Chen J, Lin Z, Tang X, et al:
S-nitrosylation-mediated coupling of G-protein alpha-2 with CXCR5
induces Hippo/YAP-dependent diabetes-accelerated atherosclerosis.
Nat Commun. 12:44522021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wei F, Wang A, Wang Q, Han W, Rong R, Wang
L, Liu S, Zhang Y, Dong C and Li Y: Plasma endothelial
cells-derived extracellular vesicles promote wound healing in
diabetes through YAP and the PI3K/Akt/mTOR pathway. Aging (Albany
NY). 12:12002–12018. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ortillon J, Le Bail JC, Villard E, Léger
B, Poirier B, Girardot C, Beeske S, Ledein L, Blanchard V, Brieu P,
et al: High glucose activates YAP signaling to promote vascular
inflammation. Front Physiol. 12:6659942021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nguyen CDK and Yi C: YAP/TAZ signaling and
resistance to cancer therapy. Trends Cancer. 5:283–296. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Konno T, Kohno T, Okada T, Shimada H,
Satohisa S, Kikuchi S, Saito T and Kojima T: ASPP2 suppression
promotes malignancy via LSR and YAP in human endometrial cancer.
Histochem Cell Biol. 154:197–213. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu G, Murshed A, Li H, Ma J, Zhen N, Ding
M, Zhu J, Mao S, Tang X, Liu L, et al: O-GlcNAcylation enhances
sensitivity to RSL3-induced ferroptosis via the YAP/TFRC pathway in
liver cancer. Cell Death Discov. 7:832021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Safran M, Dalah I, Alexander J, Rosen N,
Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, et al:
GeneCards version 3: The human gene integrator. Database (Oxford).
2010:baq0202010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Wu J, Tan Z, Li H, Lin M, Jiang Y, Liang
L, Ma Q, Gou J, Ning L, Li X and Guan F: Melatonin reduces
proliferation and promotes apoptosis of bladder cancer cells by
suppressing O-GlcNAcylation of cyclin-dependent-like kinase 5. J
Pineal Res. 71:e127652021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Takeuchi T, Horimoto Y, Oyama M, Nakatani
S, Kobata K, Tamura M, Arata Y and Hatanaka T: Osteoclast
differentiation is suppressed by increased O-GlcNAcylation due to
thiamet G treatment. Biol Pharm Bull. 43:1501–1505. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang J, Song T, Zhou S and Kong X: YAP
promotes the malignancy of endometrial cancer cells via regulation
of IL-6 and IL-11. Mol Med. 25:322019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsujiura M, Mazack V, Sudol M, Kaspar HG,
Nash J, Carey DJ and Gogoi R: Yes-associated protein (YAP)
modulates oncogenic features and radiation sensitivity in
endometrial cancer. PLoS One. 9:e1009742014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng Y, Huang H, Han Y and Zhu Y:
Expression of YAP in endometrial carcinoma tissues and its effect
on epithelial to mesenchymal transition. Transl Cancer Res.
9:7248–7258. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yan F, Qian M, He Q, Zhu H and Yang B: The
posttranslational modifications of Hippo-YAP pathway in cancer.
Biochim Biophys Acta Gen Subj. 1864:1293972020. View Article : Google Scholar
|
|
39
|
Ni W, Yao S, Zhou Y, Liu Y, Huang P, Zhou
A, Liu J, Che L and Li J: Long noncoding RNA GAS5 inhibits
progression of colorectal cancer by interacting with and triggering
YAP phosphorylation and degradation and is negatively regulated by
the m6A reader YTHDF3. Mol Cancer. 18:1432019.
View Article : Google Scholar
|
|
40
|
Wang R, Du Y, Shang J, Dang X and Niu G:
PTPN14 acts as a candidate tumor suppressor in prostate cancer and
inhibits cell proliferation and invasion through modulating
LATS1/YAP signaling. Mol Cell Probes. 53:1016422020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu
X, Zhu G, Zhao Y, Chen Y, Yu Y, et al: The essential role of YAP
O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat
Commun. 8:152802017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Peng C, Zhu Y, Zhang W, Liao Q, Chen Y,
Zhao X, Guo Q, Shen P, Zhen B, Qian X, et al: Regulation of the
Hippo-YAP pathway by glucose sensor O-GlcNAcylation. Mol Cell.
68:591–604 e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shen YW, Zhou YD, Chen HZ, Luan X and
Zhang WD: Targeting CTGF in cancer: An emerging therapeutic
opportunity. Trends Cancer. 7:511–524. 2021. View Article : Google Scholar
|
|
44
|
Li XT, Li JY, Zeng GC, Lu L, Jarrett MJ,
Zhao Y, Yao QZ, Chen X and Yu KJ: Overexpression of connective
tissue growth factor is associated with tumor progression and
unfavorable prognosis in endometrial cancer. Cancer Biomark.
25:295–302. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Krzeslak A, Wojcik-Krowiranda K, Forma E,
Jozwiak P, Romanowicz H, Bienkiewicz A and Brys M: Expression of
GLUT1 and GLUT3 glucose transporters in endometrial and breast
cancers. Pathol Oncol Res. 18:721–728. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
MacLaughlan SD, Palomino WA, Mo B, Lewis
TD, Lininger RA and Lessey BA: Endometrial expression of Cyr61: A
marker of estrogenic activity in normal and abnormal endometrium.
Obstet Gynecol. 110:146–154. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim H, Son S, Ko Y, Lee JE, Kim S and Shin
I: YAP, CTGF and Cyr61 are overexpressed in tamoxifen-resistant
breast cancer and induce transcriptional repression of ERα. J Cell
Sci. 134:jcs2565032021. View Article : Google Scholar
|
|
48
|
Kuo CC, Ling HH, Chiang MC, Chung CH, Lee
WY, Chu CY, Wu YC, Chen CH, Lai YW, Tsai IL, et al: Metastatic
colorectal cancer rewrites metabolic program through a
Glut3-YAP-dependent signaling circuit. Theranostics. 9:2526–2540.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kuo CY, Chang YC, Chien MN, Jhuang JY, Hsu
YC, Huang SY and Cheng SP: SREBP1 promotes invasive phenotypes by
upregulating CYR61/CTGF via the Hippo-YAP pathway. Endocr Relat
Cancer. 29:47–58. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cheng X and Hart GW: Alternative
O-glycosylation/O-phosphorylation of serine-16 in murine estrogen
receptor beta: Post-translational regulation of turnover and
transactivation activity. J Biol Chem. 276:10570–10575. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hardivillé S, Hoedt E, Mariller C,
Benaïssa M and Pierce A: O-GlcNAcylation/phosphorylation cycling at
Ser10 controls both transcriptional activity and stability of
delta-lactoferrin. J Biol Chem. 285:19205–19218. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rani L, Mittal J and Mallajosyula SS:
Effect of phosphorylation and O-GlcNAcylation on proline-rich
domains of tau. J Phys Chem B. 124:1909–1918. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fu Y, Ning L, Feng J, Yu X, Guan F and Li
X: Dynamic regulation of O-GlcNAcylation and phosphorylation on
STAT3 under hypoxia-induced EMT. Cell Signal. 93:1102772022.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Whelan SA, Lane MD and Hart GW: Regulation
of the O-linked beta-N-acetylglucosamine transferase by insulin
signaling. J Biol Chem. 283:21411–21417. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li X, Wu Z, He J, Jin Y, Chu C, Cao Y, Gu
F, Wang H, Hou C, Liu X and Zou Q: OGT regulated O-GlcNAcylation
promotes papillary thyroid cancer malignancy via activating YAP.
Oncogene. 40:4859–4871. 2021. View Article : Google Scholar : PubMed/NCBI
|
